Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

9 results
12:00 AM, Nov 07, 2005  |  BioCentury | Finance

EPS watch

37.81 $2.31 7% $384.7 $6,297.4 The decline in EPS vs. 3Q04 reflects generic competition for Agrylin/Xagrid
anagrelide. The drug for essential thrombocythemia posted 3Q05 sales of $16.8M, down 66% from 3Q04. ADHD …
12:00 AM, May 02, 2005  |  BioCentury | Finance

Ebb & Flow

Excluding de-stocking, SHP said the drug would have had 18% growth. Sales of cardiovascular drug Agrylin
Xagrid in the EU) also suffered from de-stocking and provisions for returns following the approval …
may have liked the drug's prospects in Europe, where it was approved in November 2004. Xagrid's …
12:00 AM, Jan 03, 2005  |  BioCentury | Finance

Follow the winners

to treat high phosphate in patients with end-stage renal disease (ESRD), while Europe approved SHP's Xagrid
anagrelide for essential thrombocythemia. Despite a strong presence on the approval list, the big cap biotechs …
12:00 AM, Jan 03, 2005  |  BioCentury | Finance

4Q approvals

Fosrenol lanthanum to treat high blood phosphate levels in end-stage renal disease (ESRD) EU approves Xagrid
anagrelide as second-line monotherapy to treat essential thrombocythemia (ET) 4Q setbacks Selected fourth quarter product setbacks …
12:00 AM, Nov 22, 2004  |  BioCentury | Finance

Ebb & Flow

LSE:SHP; SHPGY) was up 1.5p to 532.3p on the week after receiving EU approval for Xagrid
anagrelide as a second-line monotherapy to treat essential thrombocythemia (ET). The compound, which is marketed in …
the U.S. as Agrylin , had sales of $132.5 million in 2003. On NASDAQ, SHPGY finished …
12:00 AM, Mar 15, 2004  |  BioCentury | Finance

Ebb & Flow

from $1 billion in 2002, mainly driven by Adderall XR once-daily treatment for ADHD and Agrylin
12:00 AM, Jul 28, 2003  |  BioCentury | Finance

Ebb & Flow

SHPGY) was up 15.5p to 462.3p on the week, as the CPMP recommended approval of Xagrid
anagrelide to reduce platelet count in essential thrombocythemia patients. SHP markets Xagrid in the U.S. under …
the name Agrylin , where it had sales of $119 million last year. Also last week …
12:00 AM, Apr 01, 2002  |  BioCentury | Finance

Europe: All news is bad news

on the quarter. Last Thursday, SHP submitted an MAA for European marketing approval of its Xagrid
anagrelide to treat essential thrombocythemia. The treatment already is marketed in the U.S. as Agrylin
quarters, Phase III and approval news looks thin. Beyond SHP's filing for European approval of Agrylin
12:00 AM, Apr 01, 2002  |  BioCentury | Finance

Ebb & Flow

analysts had expected. Also last week, SHP submitted an MAA for European marketing approval of Xagrid
anagrelide to treat essential thrombocythemia. The treatment is marketed in the U.S. as Agrylin . On …